One of the comparisons in BIG 1-98 was the effect of monotherapy with letrozole (an aromatase inhibitor) or tamoxifen as adjuvant endocrine therapy for postmenopausal women with hormone receptor–positive breast cancer on the risk of death. Here, NR4A1 is linked to breast cancer.